EPS for Integra LifeSciences Holdings Corporation (IART) Expected At $0.56

February 21, 2018 - By Winifred Garcia

 EPS for Integra LifeSciences Holdings Corporation (IART) Expected At $0.56
Investors sentiment increased to 1.29 in Q3 2017. Its up 0.15, from 1.14 in 2017Q2. It improved, as 22 investors sold Integra LifeSciences Holdings Corporation shares while 60 reduced holdings. 26 funds opened positions while 80 raised stakes. 68.21 million shares or 2.93% more from 66.26 million shares in 2017Q2 were reported.
Arizona State Retirement Sys has 0.02% invested in Integra LifeSciences Holdings Corporation (NASDAQ:IART). Numeric Investors Ltd Liability Co reported 9,300 shares stake. Commonwealth Equity Ser Incorporated invested in 0% or 9,370 shares. Rafferty Asset Ltd Limited Liability Company invested in 14,704 shares. Envestnet Asset Mgmt accumulated 13,365 shares. New York-based Jpmorgan Chase And Com has invested 0% in Integra LifeSciences Holdings Corporation (NASDAQ:IART). Natixis has 80,412 shares. Fifth Third National Bank reported 1,652 shares. Assetmark stated it has 4,332 shares. Sei Invs Company owns 0.03% invested in Integra LifeSciences Holdings Corporation (NASDAQ:IART) for 177,525 shares. 38,500 are held by Thrivent Fincl For Lutherans. Comml Bank Of Montreal Can reported 9,029 shares. World Asset Mngmt reported 4,226 shares. Teachers Retirement Systems Of The State Of Kentucky holds 0.02% of its portfolio in Integra LifeSciences Holdings Corporation (NASDAQ:IART) for 35,366 shares. Geode Cap Ltd Liability Corporation reported 560,818 shares stake.

Analysts expect Integra LifeSciences Holdings Corporation (NASDAQ:IART) to report $0.56 EPS on February, 27 before the open.They anticipate $0.04 EPS change or 7.69 % from last quarter’s $0.52 EPS. IART’s profit would be $43.95M giving it 23.29 P/E if the $0.56 EPS is correct. After having $0.45 EPS previously, Integra LifeSciences Holdings Corporation’s analysts see 24.44 % EPS growth. The stock increased 1.05% or $0.54 during the last trading session, reaching $52.17. About 612,330 shares traded or 28.99% up from the average. Integra LifeSciences Holdings Corporation (NASDAQ:IART) has risen 32.67% since February 22, 2017 and is uptrending. It has outperformed by 15.97% the S&P500.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) Ratings Coverage

Among 15 analysts covering Integra Lifesciences Holdings Corp. (NASDAQ:IART), 8 have Buy rating, 0 Sell and 7 Hold. Therefore 53% are positive. Integra Lifesciences Holdings Corp. had 35 analyst reports since July 29, 2015 according to SRatingsIntel. As per Monday, August 3, the company rating was upgraded by JP Morgan. As per Thursday, November 9, the company rating was maintained by RBC Capital Markets. The firm earned “Hold” rating on Wednesday, August 26 by Lake Street. The stock has “Market Perform” rating by Raymond James on Tuesday, January 2. UBS initiated Integra LifeSciences Holdings Corporation (NASDAQ:IART) rating on Monday, December 12. UBS has “Buy” rating and $96 target. As per Monday, September 21, the company rating was upgraded by Bank of America. As per Thursday, June 2, the company rating was maintained by Barclays Capital. The company was upgraded on Friday, October 28 by Lake Street. On Wednesday, June 7 the stock rating was maintained by UBS with “Buy”. On Friday, October 27 the stock rating was downgraded by J.P. Morgan to “Hold”.

Integra LifeSciences Holdings Corporation develops, makes, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company has market cap of $4.09 billion. The firm operates through two divisions, Specialty Surgical Solutions; and Orthopedics and Tissue Technologies. It has a 85.38 P/E ratio. It offers neurosurgery and critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment.

More notable recent Integra LifeSciences Holdings Corporation (NASDAQ:IART) news were published by: Nasdaq.com which released: “Integra LifeSciences Holdings (IART) Shares Cross Below 200 DMA” on February 08, 2018, also Seekingalpha.com with their article: “Integra LifeSciences Holdings (IART) Q2 2017 Results – Earnings Call Transcript” published on July 26, 2017, Zacks.com published: “Integra LifeSciences Global Prospects Solid, Competition Rife” on February 02, 2018. More interesting news about Integra LifeSciences Holdings Corporation (NASDAQ:IART) were released by: Seekingalpha.com and their article: “Integra LifeSciences Holdings’ (IART) CEO Peter Arduini on Q3 2017 Results …” published on October 26, 2017 as well as Globenewswire.com‘s news article titled: “Integra LifeSciences to Host Fourth Quarter 2017 Earnings Results Conference …” with publication date: February 01, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.